NEWSROOM

MEDIA CONTACTS

 

media@galderma.com

Christian Marcoux, Chief Communications Officer: +41 76 315 26 50

Sébastien Cros, Corporate Communications Director: +41 79 529 59 85 

Filter news by date

4 . 28 . 2021

 

Galderma acts on workplace health and safety

4 . 21 . 2021

 

#RosaceaUnmasked by Galderma unites the rosacea community to shine light on the impact of essential COVID-19 mask-wearing this Rosacea Awareness Month

4 . 8 . 2021

 

Galderma announces publication of phase 2b trial results demonstrating the rapid and long-lasting benefits of nemolizumab in clinical trial subjects with uncontrolled atopic dermatitis

4 . 6 . 2021

 

Unveiling the new Galderma!

3 . 10 . 2021

 

Galderma online survey reveals almost two thirds of rosacea patients* are experiencing worsening of signs and symptoms related to essential COVID-19 mask wearing

3 . 4 . 2021

Press Releases  

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe

2 . 4 . 2021

Press Releases  

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

11 . 18 . 2020

Press Releases  

Galderma launches Dysport® in China for treatment of glabellar lines

11 . 17 . 2020

Press Releases  

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

10 . 9 . 2020

Press Releases  

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

6 . 10 . 2020

Press Releases  

Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing

5 . 12 . 2020

Press Releases  

Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year